Mazdutide
vs Retatrutide.
Compare mazdutide and retatrutide by dual versus triple receptor mechanism, China approval, Phase 3 results, trial populations, FDA status, and evidence limits.
Also searched as IBI362 vs LY3437943 · dual agonist vs triple agonist · China approval comparison
Mazdutide vs Retatrutide: What is the difference?
Mazdutide and retatrutide are different once-weekly peptide drugs with no head-to-head trial. Mazdutide activates GLP-1 and glucagon receptors and has Chinese approvals for chronic weight management and type 2 diabetes. Retatrutide also activates the GIP receptor and remains investigational, with Phase 3 obesity results but no marketing approval. Neither drug is FDA approved. Mazdutide's China approval does not create approval or legitimate supply in the United States or another country, and separate Phase 3 percentages cannot determine which drug is more effective, safer, or more appropriate for an individual.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
Mazdutide
Approved in China for chronic weight management and type 2 diabetes; not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 37 matched NCT records
- Sponsor
- Innovent Biologics; licensed from Eli Lilly for China
Retatrutide
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 34 matched NCT records
- Sponsor
- Eli Lilly and Company
Mazdutide vs Retatrutide: how direct is the evidence?
No participant in the cited sources was randomized between Mazdutide and Retatrutide. Identity, mechanism, route, trial design, and regulatory status can be compared. Subtracting percentages from separate studies would create a treatment effect the evidence did not test.
Mazdutide
GLP-1 and glucagon receptor dual agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- China approvals active; Phase 3 and indication-expansion studies continue
- Status
- Approved in China for chronic weight management and type 2 diabetes; not FDA approved
Two evidence records, no shared randomization.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
No randomized head-to-head trialRetatrutide
GIP + GLP-1 + glucagon receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program reporting results
- Status
- Investigational - not FDA approved
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
matched NCT records
- Recruiting
- 10
- Results posted
- 1
- Recruiting site observations
- 73
matched NCT records
- Recruiting
- 2
- Results posted
- 2
- Recruiting site observations
- 450
Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
Answer the question without inventing a winner.
Each answer keeps route, mechanism, development stage, and trial result attached to the evidence that produced the fact.
Is Mazdutide better than Retatrutide?
No head-to-head trial establishes mazdutide or retatrutide as better. Mazdutide has China-specific approvals and GLORY Phase 3 results. Retatrutide remains investigational and has reported TRIUMPH Phase 3 results. The programs used different populations, countries, doses, durations, placebo responses, and analysis methods, so their headline percentages cannot produce a valid superiority ranking.
Is Mazdutide approved in the United States?
No. Mazdutide is approved in China for chronic weight management and type 2 diabetes, but the current cited records do not show FDA approval. A China approval does not authorize a US product, validate an online vial, establish pharmacy access, or transfer the approved indication to another country.
Mazdutide
GLP-1 and glucagon receptor dual agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- China approvals active; Phase 3 and indication-expansion studies continue
- Status
- Approved in China for chronic weight management and type 2 diabetes; not FDA approved
- Featured trial anchors
- NCT05607680 · NCT06164873 · NCT06184568 · NCT05606913
Retatrutide
GIP + GLP-1 + glucagon receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program reporting results
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT05929066 · NCT05931367 · NCT05882045
Compare the field, then read the limit.
Both molecules include glucagon receptor agonism and are being studied as next-generation weight-loss drugs, but their evidence paths have diverged. Mazdutide has China-only approvals supported by Chinese Phase 3 trials. Retatrutide has a multinational Phase 3 program reporting larger headline percentages over longer study periods. A useful comparison separates receptor design, population, duration, dose, estimand, placebo response, adverse events, and jurisdiction-specific regulatory status.
| Field | Mazdutide | Retatrutide | How to interpret it |
|---|---|---|---|
| Receptor design | GLP-1 and glucagon receptor dual agonist | GIP, GLP-1, and glucagon receptor triple agonist | Retatrutide adds GIP receptor activity, but receptor count does not establish clinical superiority. |
| Regulatory status | Approved in China for weight management and type 2 diabetes; not FDA approved | Investigational Phase 3 program; not FDA approved and no marketing approval recorded | A country-specific approval and an advanced trial program are different milestones that cannot be transferred across jurisdictions. |
| Phase 3 obesity anchor | 14.01% at 48 weeks for 6 mg in GLORY-1; 16.65% at 60 weeks for 9 mg in GLORY-2 | 28.3% at 80 weeks for 12 mg in TRIUMPH-1 under an efficacy estimand | The values come from separate randomized trials with different durations, populations, doses, and estimands. |
| Population footprint | Pivotal results cited here were generated in Chinese adults | Multinational TRIUMPH studies include broader country enrollment | Population and geography affect generalizability and do not create authorization in an unapproved destination. |
| Studied route | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection | A shared route does not make the products, dose escalation, adverse-event profiles, or labels equivalent. |
Why the headline numbers do not name a winner.
GLORY-1 reported mean weight changes of 11.00% and 14.01% for 4 mg and 6 mg mazdutide at week 48, versus a 0.30% gain with placebo. GLORY-2 reported 16.65% for 9 mg at week 60 versus 1.50% with placebo. TRIUMPH-1 reported 28.3% for 12 mg retatrutide at week 80 under an efficacy estimand and 25.0% under a treatment-regimen estimand. Different countries, populations, doses, durations, placebo responses, and analysis methods prevent a direct subtraction or winner claim.
Keep the comparison honest.
- 01
Keep China NMPA approval separate from FDA approval, approval in another country, seller authority, and current local supply.
- 02
Attach every percentage to the exact dose, week, population, placebo response, estimand, and trial that produced it.
- 03
Do not treat an online vial using either name as Innovent or Lilly clinical material, an approved product, or a legitimate treatment route.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →